By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genocea Biosciences 

161 1st Street
Suite 2C
Cambridge  Massachusetts    U.S.A.
Phone: 617-876-8191 Fax: 617-500-0969



Start Up

Company News
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014 11:22:33 AM
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014 11:17:08 AM
Genocea Biosciences Elects Not To Pursue Public Offering 7/16/2014 10:40:34 AM
Genocea Biosciences Commences Public Offering Of Common Stock 7/14/2014 1:32:08 PM
Genocea Biosciences Announces Positive Top-Line 12-Month Follow-Up Data From Phase 1/2a Clinical Trial For HSV-2 Immunotherapy GEN-003 7/1/2014 9:10:25 AM
Genocea Biosciences Announces Positive Top-Line Phase 1 Results For Novel Universal Pneumococcus Vaccine Candidate GEN-004 6/23/2014 8:52:47 AM
Genocea Biosciences Reports First Quarter 2014 Financial Results 5/6/2014 7:35:22 AM
Genocea Biosciences To Announce First Quarter 2014 Financial Results On May 6, 2014 4/29/2014 10:19:06 AM
Genocea Biosciences Co-Founder Receives TIME Magazine’s TIME 100 Honor 4/24/2014 9:51:25 AM
Genocea Biosciences Appoints Jonathan Poole As Chief Financial Officer 4/7/2014 7:09:58 AM